Cargando…
An Antimitotic and Antivascular Agent BPR0L075 Overcomes Multidrug Resistance and Induces Mitotic Catastrophe in Paclitaxel-Resistant Ovarian Cancer Cells
Paclitaxel plays a major role in the treatment of ovarian cancer; however, resistance to paclitaxel is frequently observed. Thus, new therapy that can overcome paclitaxel resistance will be of significant clinical importance. We evaluated antiproliferative effects of an antimitotic and antivascular...
Autores principales: | Wang, Xiaolei, Wu, Erxi, Wu, Jun, Wang, Tian-Li, Hsieh, Hsing-Pang, Liu, Xinli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675084/ https://www.ncbi.nlm.nih.gov/pubmed/23762410 http://dx.doi.org/10.1371/journal.pone.0065686 |
Ejemplares similares
-
Tubulin-Destabilizing Agent BPR0L075 Induces Vascular-Disruption in Human Breast Cancer Mammary Fat Pad Xenografts
por: Liu, Li, et al.
Publicado: (2012) -
Evaluation of Antivascular and Antimitotic Effects of Tubulin Binding Agents in Solid Tumor Therapy
por: Nihei, Yukio, et al.
Publicado: (1999) -
Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype.
por: Speicher, L. A., et al.
Publicado: (1991) -
PCTAIRE1 promotes mitotic progression and resistance against antimitotic and apoptotic signals
por: Gillani, Syed Qaaifah, et al.
Publicado: (2022) -
Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance
por: Khongkow, P, et al.
Publicado: (2016)